|
Panel
|
AUC
|
Sensitivity (%)
|
Specificity (%)
|
P value
|
Cutoff criterion
|
95% CI of AUC
|
|---|
|
ND– vs ND+
|
|
MPP-Aβ42/40
|
0.639
|
71.8
|
51.5
|
<0.0001
|
>0.1871
|
0.559–0.719
|
|
MPP-Aβ42/40 + age + gender
|
0.695
|
79.0
|
57.8
|
<0.0001
|
>0.1864
|
0.622–0.767
|
|
MPP-Aβ42/40 + age + gender + ApoE
|
0.783
|
80.7
|
69.2
|
<0.0001
|
>0.1730
|
0.715–0.852
|
|
PiB– vs PiB+
|
|
MPP-Aβ42/40
|
0.668
|
71.0
|
52.2
|
<0.0001
|
>0.2731
|
0.605–0.731
|
|
MPP-Aβ42/40 + age + gender
|
0.682
|
71.0
|
54.2
|
<0.0001
|
>0.2759
|
0.622–0.741
|
|
MPP-Aβ42/40 + age + gender + ApoE
|
0.799
|
78.0
|
66.8
|
<0.0001
|
>0.2230
|
0.746–0.852
|
-
ApoE Apolipoprotein E, AUC area under curve, MPP mixture of protease inhibitors and phosphatase inhibitors, CI confidence interval, ROC receiver operating characteristic, – or + PiB-PET positivity, ND– PiB-PET-negative cognitively normal (CN) and PiB-PET-negative subjects with mild cognitive impairment (MCI), ND+ PiB-PET-positive CN and PiB-PET-positive MCI, PiB– grouped CN–, MCI–, and ADD–, PiB+ grouped CN+, MCI+, and ADD+
